Radiation can be used to up-regulate the expression of the somatostatin receptor (sstr) subtype 2 in small cell lung cancer (SCLC) cells at absorbed doses of 2–8 Gy. Increased sstr expression results in increased binding of radiolabeled somatostatin analogs to the tumor cell, which enhances the efficacy of systemic radionuclide therapy. The aim of this study was to determine if lower absorbed doses could up-regulate sstr2 expression, and possibly influence other sstr subtypes.
Methods:
Human H69 SCLC cells were irradiated with an absorbed dose of 0.12–6.0 Gy and the sstr mRNA expression 3 days after irradiation was measured by quantitative real-time polymerase chain reaction for sstr1–5. At the same time point was the binding of [177Lu]-DOTA0-Tyr3-octreotate to the cells measured after irradiation to an absorbed dose of 0.12–2.0 Gy and compared to the binding to nonirradiated cells.
Results:
mRNA expression of sstr1, sstr2, and sstr5 was increased by a factor of 1.5–2 in cells irradiated with absorbed doses≥4 Gy and the binding of [177Lu]-DOTA0-Tyr3-octreotate was, accordingly, 2–3 times higher to irradiated cells for all absorbed doses, except 0.25 Gy.
Conclusion:
The binding of [177Lu]-DOTA0-Tyr3-octreotate was increased after radiation exposure. This increase was observed at low absorbed doses in parallel with up-regulation of sstr1, sstr2, and sstr5 mRNA.
Get full access to this article
View all access options for this article.
References
1.
KwekkeboomDJ, De HerderWW, van EijckCHet al.Peptide receptor radionuclide therapy in patients with gastroenteropanreatic neuroendocrine tumors. Semin Nucl Med, 2010; 40:78.
2.
PoolSE, KrenningE, KoningGAet al.Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med, 2010; 40:209.
3.
SwärdC, BernhardtP, AhlmanHet al.[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: The value of measuring absorbed dose to the kidney. World J Surg, 2010; 34:1368.
4.
KwekkeboomDJ, TeunissenJJ, BakkerWHet al.Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol, 2005; 23:2754.
5.
van EssenM, KrenningEP, BakkerWHet al.Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging, 2007; 34:1219.
6.
Van EssenM, KrenningEP, De JongMet al.Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol, 2007; 46:723.
7.
AnderssonP, Forssell-AronssonE, JohansonVet al.Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med, 1996; 37:2002.
8.
De JongM, BernardBF, De BruinEet al.Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun, 1998; 19:283.
9.
HoflandLJ, van KoetsveldPM, WaaijersMet al.Internalisation of isotope-coupled somatostatin analogues. Digestion, 1996; 57,suppl1:2.
10.
StorchD, BeheM, WalterMAet al.Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: Does tumor or pancreas uptake correlate with the rate of internalization?J Nucl Med, 2005; 46:1561.
11.
DrazninB, ShermanN, SussmanKet al.Internalization and cellular processing of somatostatin in primary culture of rat anterior pituitary cells. Endocrinology, 1985; 117:960.
12.
MorelG, PelletierG, HeislerS. Internalization and subcellular distribution of radiolabeled somatostatin-28 in mouse anterior pituitary tumor cells. Endocrinology, 1986; 119:1972.
13.
ReubiJC, WaserB, SchaerJCet al.Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med, 2001; 28:836.
14.
SagmanU, MullenJB, KovacsKet al.Identification of somatostatin receptors in human small cell lung carcinoma. Cancer, 1990; 66:2129.
15.
FujitaT, YamajiY, SatoMet al.Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci, 1994; 55:1797.
16.
SchmittA, BernhardtP, NilssonOet al.Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model. J Nucl Med, 2004; 45:1542.
17.
SchmittA, BernhardtP, NilssonOet al.Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm, 2003; 18:593.
18.
ReubiJC, ScharJC, WaserBet al.Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med, 2000; 27:273.
19.
OddstigJ, BernhardtP, NilssonOet al.Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol, 2006; 33:841.
20.
BeheM, KollerS, PüskenMet al.Irradiation-induced upregulation of somatostatin and gastrin receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging, 2004; 31:S237.
21.
CapelloA, KrenningE, BernardBet al.111In-labelled somatostatin analogues in a rat tumour model: Somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging, 2005; 32:1288.
22.
AnderssonP, Forssell-AronssonE, GrétarsdóttirJet al.Biokinetics and dosimetry after repeated injections of 111In-DTPA-D-Phel-octreotide. Int Radiopharm Dosim Symp, 1996.
23.
Forssell-AronssonE, BernhardtP, NilssonOet al.Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide. Acta Oncol, 2004; 43:436.
24.
KwekkeboomDJ, BakkerWH, KooijPPet al.[177Lu-DOTAOTyr3]octreotate: Comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med, 2001; 28:1319.
25.
KölbyL, BernhardtP, AhlmanHet al.A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol, 2001; 158:745.
26.
EversBM, TownsendCMJr., UppJRet al.Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology, 1991; 101:303.
27.
de JongM, BreemanWA, BernardBFet al.[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer, 2001; 92:628.
28.
PrevostG, BourgeoisY, MormontCet al.Characterization of somatostatin receptors and growth inhibition by the somatostatin analogue BIM23014 in small cell lung carcinoma xenograft: SCLC-6. Life Sci, 1994; 55:155.
29.
BernhardtP, OddstigJ, KölbyLet al.Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice. Cancer Biother Radiopharm, 2007; 22:644.
30.
MelisM, ForrerF, CapelloAet al.Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [(177)Lu-DOTA(0),Tyr(3)]octreotate therapy. Q J Nucl Med Mol Imaging, 2007; 51:324.
31.
SchmittA, BernhardtP, NilssonOet al.Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm, 2005; 20:231.
32.
KölbyL, BernhardtP, JohansonVet al.Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer, 2005; 93:1144.
33.
D'AddonaD, CarotenutoA, NovellinoEet al.Novel sst5-selective somatostatin dicarba-analogues: Synthesis and conformation-affinity relationships. J Med Chem, 2008; 51:512.
34.
NolanLA, SchmidHA, LevyA. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology, 2007; 148:2821.
35.
ReubiJC, EisenwienerKP, RinkHet al.A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol, 2002; 456:45.
36.
WildD, SchmittJS, GinjMet al.DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging, 2003; 30:1338.
37.
DeNardoGL, SiantarCL, DeNardoSJ. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm, 2002; 17:107.
38.
ValkemaR, PauwelsSA, KvolsLKet al.Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med, 2005; 46,suppl1:83S.
39.
BrunsC, LewisI, BrinerUet al.SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol, 2002; 146,5:707.
